To V, Thio N, Castle R, Macdonald S, Molden-Hauer T, Wells J, McMahon R, Bressel M, Tran B, Azad AA, Moon D, Appu S, Wong L-M, Murphy DG, Cuff K, Pryor D, Spain L, Au L, D’Souza C, Neeson PJ, Siva S. Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma. Nature Communications. 2026;:10.1038/s41467-026-74255-x
Panasci J, Park CL, Tran B, Siu LL. Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours. British Journal of Cancer. 2026;135(1):10.1038/s41416-026-03450-w
Pan HYC, Homewood D, Lucas H, Dittmer B, Teh J, O’Brien JS, Liu J, Tran B, Chee J, Churchill JA, Lawrentschuk N, Corcoran NM. The Australian Penile Cancer Clinical Registry: a comprehensive national approach to data collection. BJU International. 2026;138(Suppl 2):10.1111/bju.70188
Sherry AD, To V, D’souza C, Kiany S, Thio N, Liu S, Sun X, Castle B, Macdonald S, Choi H, Seo A, Hara K, Pryor D, Azad A, Tran B, Au L, Spain L, Ludmir EB, Jonasch E, Tannir NM, Msaouel P, Neeson P, Haymaker C, Tang C, Siva S. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. European Urology. 2026;90(1):10.1016/j.eururo.2026.03.024
Kashyap R, Buteau JP, Papa N, Ayati N, Eifer M, Betech-Antar V, Akhurst T, Alipour R, Kong G, Saghebi J, Ravi Kumar AS, Cardin A, Sandhu S, Tran B, Azad AA, Murphy DG, Hofman MS. Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy.Journal of Nuclear Medicine. 2026;:10.2967/jnumed.126.272531
Chow KVC, Conduit C, O’Haire S, Kuchel A, Wong S, Grimison P, Weickhardt A, Pranavan G, Lynam J, Bastick P, Goh J, Sengupta S, Smith A, Liow E, Campbell D, Wong M, Zlatic K, Gibbs P, Tran B, Gan CL. Extracranial, Extragonadal Germ Cell Tumors: A Multicenter Australian Case Series. Asia-Pacific Journal of Clinical Oncology. 2026;22(3):10.1111/ajco.70083
Dorff TB, Appleman LJ, Lin C-C, Lee JL, Tran B, Fischer S, Danila D, Gokani P, Gallent B, Pook DW. XALience: A phase 3, open-label, multicenter, randomized study of xaluritamig plus abiraterone vs investigator’s choice in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.Journal of Clinical Oncology. 2026;44(16_suppl):10.1200/jco.2026.44.16_suppl.tps5144
Pan HY, Mulholland CJ, Shi W, Furrer MA, Mizrahi GR, Conduit C, Tran B, Lawrentschuk N, Thomas BC. IP13-16 ROBOTIC-ASSISTED RETROPERITONEAL LYMPH NODE DISSECTION FOR METASTATIC TESTICULAR MALIGNANCIES – A 9-YEAR COMPARATIVE ANALYSIS OF THE OUTCOMES AND LEARNING CURVE. Journal of Urology. 2026;215(5S):10.1097/01.ju.0001191348.53260.b7.16
Lucas H, Dittmer B, Stapleton P, Tran B, Corcoran NM, Sathianathen N. Artificial Intelligence Chatbots as Information Sources on Testicular Cancer: Quality, Readability and Actionability. Société Internationale d’Urologie Journal. 2026;7(2):10.3390/siuj7020027
Catto JWF, Daneshmand S, Zaucha R, Tran B, Master V, Lotan Y, Pignot G, Tubaro A, Shimizu N, Vasdev N, Lee EK, Procopio G, Galanternik F, Fischer DS, Levin TG, Zhang J, Thomas S, Stone N, Triantos S, Beeharry N. A0591 Longitudinal assessment of urine tumor DNA in high-risk non-muscle invasive bladder cancer patients. European Urology. 2026;89:10.1016/s0302-2838(26)00642-1
